Drug Discovery and Development

Drug Discovery

As a core research activity at RTI, our drug discovery and development services range from chemical synthesis and analysis to clinical drug studies.

Learn more »

Drug Design & Synthesis

Our chemists provide high-quality products and services to academic institutions; to pharmaceutical, biotech, and agrochemical companies; and to government.

Learn more »

Drug Development

Our nonclinical studies build a foundation for drug development to help determine which compounds have the greatest probability of success.

Learn more »

Drug Development & Regulatory Consulting

Our consulting team combines effective management, technical, and regulatory expertise to seamlessly plan, budget, and execute drug development projects.

Learn more »

Clinical Through Post-Approval Research

We provide scientifically rigorous research and consulting services to pharmaceutical, biotechnology, and medical device companies.

Learn more »

Our scientists pursue all facets of drug discovery and development, from synthesis and design to toxicology and metabolic analysis to comprehensive clinical trial and drug assessment services. We work with pharmaceutical companies and government agencies to bring new medicines to market, and to ensure the safety and efficacy of those in the marketplace. Show more

Our drug discovery group specializes in central nervous system drug research. Our integrated drug development capabilities include drug metabolism and pharmacokinetics, toxicology, bioanalytical services, and analytical and formulation development services. RTI Health Solutions, a business unit of RTI International, provides research and consulting services to pharmaceutical, biotechnology and medical device companies.

Courtesy of EnteroMedics Inc.

Patient preferences considered for the first time in FDA decision to approve first-of-kind obesity device

RTI Health Solutions (RTI-HS), a business unit of RTI International, partnered with the U.S. Food and Drug Administration to conduct a study on patients’ preferences which contributed to the Agency’s regulatory decision to approve the Maestro Rechargeable System, a first-of-kind device to treat obesity.

Read more